Published in Cancer Res on January 01, 2004
The regulation of cyclin D1 degradation: roles in cancer development and the potential for therapeutic invention. Mol Cancer (2007) 3.28
HDAC inhibitor PCI-24781 decreases RAD51 expression and inhibits homologous recombination. Proc Natl Acad Sci U S A (2007) 2.03
Spatiotemporal characterization of ionizing radiation induced DNA damage foci and their relation to chromatin organization. Mutat Res (2010) 1.50
Histone deacetylase inhibitor (HDACI) mechanisms of action: emerging insights. Pharmacol Ther (2014) 1.35
Antileukemia activity of the combination of an anthracycline with a histone deacetylase inhibitor. Blood (2006) 1.22
Poly(ADP-ribose) polymerase inhibitor induces accelerated senescence in irradiated breast cancer cells and tumors. Cancer Res (2010) 1.22
The role of histone deacetylases in prostate cancer. Epigenetics (2008) 1.21
DNER, an epigenetically modulated gene, regulates glioblastoma-derived neurosphere cell differentiation and tumor propagation. Stem Cells (2009) 1.20
Radiosensitization of colorectal carcinoma cell lines by histone deacetylase inhibition. Radiat Oncol (2006) 1.13
Vorinostat increases carboplatin and paclitaxel activity in non-small-cell lung cancer cells. Int J Cancer (2010) 1.13
Postradiation sensitization of the histone deacetylase inhibitor valproic acid. Clin Cancer Res (2008) 1.12
Low-dose valproic acid enhances radiosensitivity of prostate cancer through acetylated p53-dependent modulation of mitochondrial membrane potential and apoptosis. Mol Cancer Res (2011) 1.10
Vorinostat enhances the radiosensitivity of a breast cancer brain metastatic cell line grown in vitro and as intracranial xenografts. Mol Cancer Ther (2009) 1.09
Grand rounds at the National Institutes of Health: HDAC inhibitors as radiation modifiers, from bench to clinic. J Cell Mol Med (2011) 1.07
HDAC inhibitor, valproic acid, induces p53-dependent radiosensitization of colon cancer cells. Cancer Biother Radiopharm (2009) 1.06
DNMT (DNA methyltransferase) inhibitors radiosensitize human cancer cells by suppressing DNA repair activity. Radiat Oncol (2012) 1.02
Targeting MPS1 Enhances Radiosensitization of Human Glioblastoma by Modulating DNA Repair Proteins. Mol Cancer Res (2015) 1.01
DNA damage enhancement from gold nanoparticles for clinical MV photon beams. Radiat Res (2012) 0.99
Inhibitors of poly ADP-ribose polymerase (PARP) induce apoptosis of myeloid leukemic cells: potential for therapy of myeloid leukemia and myelodysplastic syndromes. Haematologica (2009) 0.99
High throughput evaluation of gamma-H2AX. Radiat Oncol (2009) 0.97
Ionizing radiation and glioblastoma exosomes: implications in tumor biology and cell migration. Transl Oncol (2013) 0.95
Upregulation of NAD(P)H:quinone oxidoreductase by radiation potentiates the effect of bioreductive beta-lapachone on cancer cells. Neoplasia (2007) 0.94
Histone deacetylase inhibition decreases proliferation and potentiates the effect of ionizing radiation in atypical teratoid/rhabdoid tumor cells. Neuro Oncol (2011) 0.91
The combination effect of sodium butyrate and 5-Aza-2'-deoxycytidine on radiosensitivity in RKO colorectal cancer and MCF-7 breast cancer cell lines. World J Surg Oncol (2009) 0.89
Histone deacetylase inhibitor, valproic acid, radiosensitizes the C6 glioma cell line in vitro. Oncol Lett (2013) 0.89
Epigenetic therapy for breast cancer. Int J Mol Sci (2011) 0.86
Molecular targets for tumor radiosensitization. Chem Rev (2009) 0.86
Combination of suberoylanilide hydroxamic acid with heavy ion therapy shows promising effects in infantile sarcoma cell lines. Radiat Oncol (2011) 0.85
Molecular staging of prostate cancer in the year 2007. World J Urol (2007) 0.85
DNA Damage Response Assessments in Human Tumor Samples Provide Functional Biomarkers of Radiosensitivity. Semin Radiat Oncol (2015) 0.84
Nanoparticle formulations of histone deacetylase inhibitors for effective chemoradiotherapy in solid tumors. Biomaterials (2015) 0.81
FOXM1 and STAT3 interaction confers radioresistance in glioblastoma cells. Oncotarget (2016) 0.80
A histone deacetylase inhibitor, trichostatin A, enhances radiosensitivity by abrogating G2/M arrest in human carcinoma cells. Cancer Res Treat (2005) 0.80
Chromatin Modulation by Histone Deacetylase Inhibitors: Impact on Cellular Sensitivity to Ionizing Radiation. Mol Cell Pharmacol (2013) 0.80
An atlas of histone deacetylase expression in breast cancer: fluorescence methodology for comparative semi-quantitative analysis. Am J Transl Res (2012) 0.80
Cripto-1 overexpression is involved in the tumorigenesis of nasopharyngeal carcinoma. BMC Cancer (2009) 0.79
Therapy of thyroid carcinoma with the histone deacetylase inhibitor MS-275. Eur J Nucl Med Mol Imaging (2010) 0.78
Vorinostat(SAHA) Promotes Hyper-Radiosensitivity in Wild Type p53 Human Glioblastoma Cells. J Clin Oncol Res (2014) 0.77
Radiosensitization of yeast cells by inhibition of histone h4 acetylation. Radiat Res (2008) 0.77
Sequence-Dependent Radiosensitization of Histone Deacetylase Inhibitors Trichostatin A and SK-7041. Cancer Res Treat (2013) 0.77
Targeting chromatin to improve radiation response. Br J Radiol (2014) 0.76
Effect of Chromatin Structure on the Extent and Distribution of DNA Double Strand Breaks Produced by Ionizing Radiation; Comparative Study of hESC and Differentiated Cells Lines. Int J Mol Sci (2016) 0.76
Histone deacetylase inhibitors decrease NHEJ both by acetylation of repair factors and trapping of PARP1 at DNA double-strand breaks in chromatin. Leuk Res (2016) 0.76
Bidirectional function of shenghe powder on repair of radiation-induced DNA damage in glioma and astrocyte. Afr J Tradit Complement Altern Med (2010) 0.75
Isotype-Specific Inhibition of Histone Deacetylases: Identification of Optimal Targets for Radiosensitization. Cancer Res Treat (2015) 0.75
Advances in epigenetic glioblastoma therapy. Oncotarget (2017) 0.75
Time dependent modulation of tumor radiosensitivity by a pan HDAC inhibitor: abexinostat. Oncotarget (2017) 0.75
Targeting the regulation of androgen receptor signaling by the heat shock protein 90 cochaperone FKBP52 in prostate cancer cells. Proc Natl Acad Sci U S A (2011) 2.58
Phase I and pharmacokinetic study of MS-275, a histone deacetylase inhibitor, in patients with advanced and refractory solid tumors or lymphoma. J Clin Oncol (2005) 2.36
Fumarate hydratase deficiency in renal cancer induces glycolytic addiction and hypoxia-inducible transcription factor 1alpha stabilization by glucose-dependent generation of reactive oxygen species. Mol Cell Biol (2009) 2.27
Swe1Wee1-dependent tyrosine phosphorylation of Hsp90 regulates distinct facets of chaperone function. Mol Cell (2010) 2.24
HDAC inhibitors in cancer care. Oncology (Williston Park) (2010) 2.20
Phase 1 and pharmacologic study of MS-275, a histone deacetylase inhibitor, in adults with refractory and relapsed acute leukemias. Blood (2007) 2.15
Threonine 22 phosphorylation attenuates Hsp90 interaction with cochaperones and affects its chaperone activity. Mol Cell (2011) 1.94
Spartin regulates synaptic growth and neuronal survival by inhibiting BMP-mediated microtubule stabilization. Neuron (2013) 1.83
Transcriptional signature of flavopiridol-induced tumor cell death. Mol Cancer Ther (2004) 1.80
Inhibition of histone deacetylation: a strategy for tumor radiosensitization. J Clin Oncol (2007) 1.77
Influence of in vivo growth on human glioma cell line gene expression: convergent profiles under orthotopic conditions. Proc Natl Acad Sci U S A (2005) 1.77
CD133+ glioblastoma stem-like cells are radiosensitive with a defective DNA damage response compared with established cell lines. Clin Cancer Res (2009) 1.72
Physiologic oxygen concentration enhances the stem-like properties of CD133+ human glioblastoma cells in vitro. Mol Cancer Res (2009) 1.69
Molecular and cellular biology of moderate-dose (1-10 Gy) radiation and potential mechanisms of radiation protection: report of a workshop at Bethesda, Maryland, December 17-18, 2001. Radiat Res (2003) 1.69
Inhibition of hsp90 compromises the DNA damage response to radiation. Cancer Res (2006) 1.68
Regulation of leukemic cell adhesion, proliferation, and survival by beta-catenin. Blood (2002) 1.65
Phase II trial of bevacizumab, thalidomide, docetaxel, and prednisone in patients with metastatic castration-resistant prostate cancer. J Clin Oncol (2010) 1.65
Enhancement of in vitro and in vivo tumor cell radiosensitivity by valproic acid. Int J Cancer (2005) 1.56
Gleevec-mediated inhibition of Rad51 expression and enhancement of tumor cell radiosensitivity. Cancer Res (2003) 1.53
Histone deacetylase inhibitors in cancer therapy. Curr Opin Oncol (2008) 1.44
Curcumin is an inhibitor of p300 histone acetylatransferase. Med Chem (2006) 1.44
In vitro and in vivo radiosensitization of glioblastoma cells by the poly (ADP-ribose) polymerase inhibitor E7016. Clin Cancer Res (2009) 1.44
Radiation-induced changes in gene expression involve recruitment of existing messenger RNAs to and away from polysomes. Cancer Res (2006) 1.38
Hsp90, not Grp94, regulates the intracellular trafficking and stability of nascent ErbB2. Cell Stress Chaperones (2002) 1.37
Molecular chaperone TRAP1 regulates a metabolic switch between mitochondrial respiration and aerobic glycolysis. Proc Natl Acad Sci U S A (2013) 1.37
Phase II study of belinostat in patients with recurrent or refractory advanced thymic epithelial tumors. J Clin Oncol (2011) 1.36
Dynamic tyrosine phosphorylation modulates cycling of the HSP90-P50(CDC37)-AHA1 chaperone machine. Mol Cell (2012) 1.35
In vitro and in vivo radiosensitization induced by the DNA methylating agent temozolomide. Clin Cancer Res (2008) 1.29
Inhibition of Hsp90 activates osteoclast c-Src signaling and promotes growth of prostate carcinoma cells in bone. Proc Natl Acad Sci U S A (2008) 1.28
Phase I trial of MS-275, a histone deacetylase inhibitor, administered weekly in refractory solid tumors and lymphoid malignancies. Clin Cancer Res (2007) 1.27
STA-9090, a small-molecule Hsp90 inhibitor for the potential treatment of cancer. Curr Opin Investig Drugs (2010) 1.27
Inhibition of Hsp90: a multitarget approach to radiosensitization. Clin Cancer Res (2007) 1.25
Enhanced tumor cell radiosensitivity and abrogation of G2 and S phase arrest by the Hsp90 inhibitor 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin. Clin Cancer Res (2004) 1.23
The brain microenvironment preferentially enhances the radioresistance of CD133(+) glioblastoma stem-like cells. Neoplasia (2012) 1.23
Enhanced cell killing induced by the combination of radiation and the heat shock protein 90 inhibitor 17-allylamino-17- demethoxygeldanamycin: a multitarget approach to radiosensitization. Clin Cancer Res (2003) 1.22
Hsp90 charged-linker truncation reverses the functional consequences of weakened hydrophobic contacts in the N domain. Nat Struct Mol Biol (2009) 1.22
Abrogation of p21 expression by flavopiridol enhances depsipeptide-mediated apoptosis in malignant pleural mesothelioma cells. Clin Cancer Res (2004) 1.22
Gene expression profiling of ATL patients: compilation of disease-related genes and evidence for TCF4 involvement in BIRC5 gene expression and cell viability. Blood (2009) 1.21
Interactions between Shh, Sostdc1 and Wnt signaling and a new feedback loop for spatial patterning of the teeth. Development (2011) 1.21
A phase I study of PF-04929113 (SNX-5422), an orally bioavailable heat shock protein 90 inhibitor, in patients with refractory solid tumor malignancies and lymphomas. Clin Cancer Res (2011) 1.20
DNA methyltransferase 1 and 3B activate BAG-1 expression via recruitment of CTCFL/BORIS and modulation of promoter histone methylation. Cancer Res (2008) 1.17
Enhancement of xenograft tumor radiosensitivity by the histone deacetylase inhibitor MS-275 and correlation with histone hyperacetylation. Clin Cancer Res (2004) 1.17
Enhancement of in vitro and in vivo tumor cell radiosensitivity by the DNA methylation inhibitor zebularine. Clin Cancer Res (2005) 1.15
Postradiation sensitization of the histone deacetylase inhibitor valproic acid. Clin Cancer Res (2008) 1.12
Aryl hydrocarbon receptor activation of an antitumor aminoflavone: basis of selective toxicity for MCF-7 breast tumor cells. Mol Cancer Ther (2004) 1.12
Histone deacetylation as a target for radiosensitization. Curr Top Dev Biol (2006) 1.11
Post-radiation increase in VEGF enhances glioma cell motility in vitro. Radiat Oncol (2012) 1.11
Transcriptional regulation of the transforming growth factor beta type II receptor gene by histone acetyltransferase and deacetylase is mediated by NF-Y in human breast cancer cells. J Biol Chem (2001) 1.10
Inhibition of Akt by the alkylphospholipid perifosine does not enhance the radiosensitivity of human glioma cells. Mol Cancer Ther (2006) 1.09
Orthotopic growth of human glioma cells quantitatively and qualitatively influences radiation-induced changes in gene expression. Cancer Res (2005) 1.09
Antisense oligonucleotides targeted to the human alpha folate receptor inhibit breast cancer cell growth and sensitize the cells to doxorubicin treatment. Mol Cancer Ther (2004) 1.09
Drosophila Atlastin regulates the stability of muscle microtubules and is required for synapse development. Dev Biol (2009) 1.09
Englerin A stimulates PKCθ to inhibit insulin signaling and to simultaneously activate HSF1: pharmacologically induced synthetic lethality. Cancer Cell (2013) 1.08
ErbB3 expression predicts tumor cell radiosensitization induced by Hsp90 inhibition. Cancer Res (2005) 1.07
Grand rounds at the National Institutes of Health: HDAC inhibitors as radiation modifiers, from bench to clinic. J Cell Mol Med (2011) 1.07
Comparative effects of lovastatin on mammary and prostate oncogenesis in transgenic mouse models. Carcinogenesis (2003) 1.07
Dietary Aloe Vera Supplementation Improves Facial Wrinkles and Elasticity and It Increases the Type I Procollagen Gene Expression in Human Skin in vivo. Ann Dermatol (2009) 1.06
Astrocytes enhance the invasion potential of glioblastoma stem-like cells. PLoS One (2013) 1.06
Microenvironmental regulation of glioblastoma radioresponse. Clin Cancer Res (2010) 1.05
Effect of radiation and ibuprofen on normoxic renal carcinoma cells overexpressing hypoxia-inducible factors by loss of von Hippel-Lindau tumor suppressor gene function. Clin Cancer Res (2004) 1.05
A phase II study of perifosine in androgen independent prostate cancer. Cancer Biol Ther (2005) 1.04
Ex vivo rapamycin generates apoptosis-resistant donor Th2 cells that persist in vivo and prevent hemopoietic stem cell graft rejection. J Immunol (2008) 1.04
Salen Mn complexes mitigate radiation injury in normal tissues. Anticancer Agents Med Chem (2011) 1.03
In vitro and in vivo radiosensitization induced by the ribonucleotide reductase inhibitor Triapine (3-aminopyridine-2-carboxaldehyde-thiosemicarbazone). Clin Cancer Res (2006) 1.03
Radiosensitization of glioma cells by modulation of Met signalling with the hepatocyte growth factor neutralizing antibody, AMG102. J Cell Mol Med (2010) 1.03
Aryl hydrocarbon receptor mediates sensitivity of MCF-7 breast cancer cells to antitumor agent 2-(4-amino-3-methylphenyl) benzothiazole. Mol Pharmacol (2002) 1.03
Aurora A, Aurora B and survivin are novel targets of transcriptional regulation by histone deacetylase inhibitors in non-small cell lung cancer. Cancer Biol Ther (2008) 1.03
Activation of the unfolded protein response contributes toward the antitumor activity of vorinostat. Neoplasia (2010) 1.02
Inhibition of tumor metastasis by a growth factor receptor bound protein 2 Src homology 2 domain-binding antagonist. Cancer Res (2007) 1.01
Patterning the size and number of tooth and its cusps. Dev Biol (2007) 1.01
Chromosomal protein HMGN1 modulates the expression of N-cadherin. FEBS J (2005) 1.01
The HSP90 inhibitor ganetespib synergizes with the MET kinase inhibitor crizotinib in both crizotinib-sensitive and -resistant MET-driven tumor models. Cancer Res (2013) 1.00
Radiation-induced gene translation profiles reveal tumor type and cancer-specific components. Cancer Res (2008) 1.00
Ibuprofen-mediated reduction of hypoxia-inducible factors HIF-1alpha and HIF-2alpha in prostate cancer cells. Clin Cancer Res (2003) 1.00
The primary enamel knot determines the position of the first buccal cusp in developing mice molars. Differentiation (2007) 0.97
High throughput evaluation of gamma-H2AX. Radiat Oncol (2009) 0.97
Inhibition of tumor cell motility by the interferon-inducible GTPase MxA. J Biol Chem (2009) 0.97
Contributions of co-chaperones and post-translational modifications towards Hsp90 drug sensitivity. Future Med Chem (2013) 0.96
The mTORC1/mTORC2 inhibitor AZD2014 enhances the radiosensitivity of glioblastoma stem-like cells. Neuro Oncol (2013) 0.96
Evaluation of VITEK 2, MicroScan, and Phoenix for identification of clinical isolates and reference strains. Diagn Microbiol Infect Dis (2011) 0.95
Wnt11/Fgfr1b cross-talk modulates the fate of cells in palate development. Dev Biol (2007) 0.95
The prognostic value of nestin expression in newly diagnosed glioblastoma: report from the Radiation Therapy Oncology Group. Radiat Oncol (2008) 0.95
In vivo tumor imaging in mice with near-infrared labeled endostatin. Mol Cancer Ther (2004) 0.95
Translation initiation factor eIF4E is a target for tumor cell radiosensitization. Cancer Res (2012) 0.94
Posttranslational modification and conformational state of heat shock protein 90 differentially affect binding of chemically diverse small molecule inhibitors. Oncotarget (2013) 0.93
Combining radiation and molecular targeting in cancer therapy. Cancer Biol Ther (2004) 0.93